CNN takes a look at the commercial end of the stem cell research and development pipeline: "Two biotechs, Cytori Therapeutics and Osiris Therapeutics, each hope to get their experimental stem cell products approved by the Food and Drug Administration and into the U.S. market by 2008. ... Cytori is planning to launch its first stem cell medical device in Europe this year [using] stem cell technology to rebuild breast tissue in cancer survivors. ... Osiris, [currently] has the only stem cell-based product that's been approved by the FDA. OsteoCell, which stimulates bone growth and is already on the U.S. market, is actually considered an implant rather than a drug or device. ... Prochymal, a potential treatment for acute Graft vs. Host Disease (also known as GVHD) and Crohn's disease, is in late-stage trials." Applications are narrow, incremental and slow in coming because the regulatory regime forces development in this direction; this becomes the cost-effective path, rather than anything more ambitious.